ThecaFlex Investigational Device for the Treatment of SMA



Subscribe to be notified of changes or updates to this page.

10 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by the degeneration of spinal cord motor neurons, resulting in progressive muscle weakness, paralysis, and atrophy. One treatment option available to patients is called nusinersen. This medication is administered by lumbar puncture (LP; a needle inserted between the bones of your spine) every 4 months after the initial 4 loading doses.

Lumbar puncture, however, can be challenging for some patients due to the presence of spine deformity caused by the disease. Additionally, children usually require anesthesia for this procedure. This study will be utilizing a new investigational research device, called the ThecaFlex DRx (Alcyone Therapeutics) system as an alternative to repeated lumbar puncture.

The ThecaFlex DRx system is a port and catheter that is surgically implanted to provide access to the space between the bones of your spine to avoid the need for repeated lumbar puncture and repeated anesthesia. After the device is inserted, the prescribed nusinersen is administered via the port located just beneath the skin near your abdomen. The catheter guides the medication to the intrathecal space, where it needs to be delivered.

You/your child may qualify for this study if you/they are:

  • diagnosed with SMA and are prescribed nusinersen (Spinraza) treatment
  • older than 3 years of age
  • resistant to lumbar puncture

It is important to note that this study is the first in human for this device and it has not yet been approved by the FDA.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at gogels [at] or 267-426-5433. Identifier

Eligibility & Criteria

IRB #:
Official Title:
Safety and Performance of the ThecaFlex DRx™ System Port and Catheter for Chronic Intrathecal Access, Cerebrospinal Fluid (CSF) Aspiration, and Delivery of Nusinersen in Spinal Muscular Atrophy (SMA) Patients Resistant to Lumbar PunctuRE (PIERRE) Trial
Study Phase:
Eligible Age Range:
7 - 18 Years
Study Categories: